CA2243427A1 - Nouveaux derives de pyridinecarboxamide - Google Patents

Nouveaux derives de pyridinecarboxamide Download PDF

Info

Publication number
CA2243427A1
CA2243427A1 CA002243427A CA2243427A CA2243427A1 CA 2243427 A1 CA2243427 A1 CA 2243427A1 CA 002243427 A CA002243427 A CA 002243427A CA 2243427 A CA2243427 A CA 2243427A CA 2243427 A1 CA2243427 A1 CA 2243427A1
Authority
CA
Canada
Prior art keywords
carboxamide
pyridine
piperazinyl
formula
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002243427A
Other languages
English (en)
Inventor
Norio Oshida
Hiroaki Satoh
Shinji Yokoyama
Yukiko Muraki
Kazumi Nishimura
Tamiko Hamada
Einosuke Sakurai
Hiroshi Sakai
Toshiji Sugai
Tomomi Tonoike
Koichi Itoh
Yoji Mimaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nisshin Seifun Group Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2243427A1 publication Critical patent/CA2243427A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/067—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne de nouveaux dérivés de pyridinecarboxamide représentés par la formule générale (1) ou leurs sels physiologiquement acceptables. Dans la formule, n représente un entier compris entre 14 et 18; et R représente hydrogène ou alkyle C¿1?-C¿4? linéaire ou ramifié. Ces composés sont extrêmement efficaces pour inhiber un oedème cérébral, en particulier un oedème cérébral ischémique, et inhiber la mort neuronale différée (ou inhiber l'afflux de calcium dans les neurones). Ils s'utilisent comme inhibiteur de l'oedème cérébral ou comme remède aux troubles cérébrovasculaires, car l'oedème cérébral constitue un état pathologique accompagnant les troubles cérébrovasculaires, en particulier du type de ceux qui sont observés en phase aiguë. Ces composés ne provoquent pas d'hypotension et ne présentent pratiquement aucune activité affectant le comportement, deux effets étant supposés être des effets secondaires dans la thérapie des troubles cérébrovasculaires en phase aiguë. Ils constituent par conséquent un excellent remède à ces troubles. En outre, ils ont un effet protecteur sur le cerveau (par ex. un effet antianoxique), augmentent le flux sanguin dans le cerveau, et inhibent la péroxydation lipidique, ce qui renforce leur utilité comme remède aux troubles cérébrovasculaires.
CA002243427A 1996-11-19 1997-11-19 Nouveaux derives de pyridinecarboxamide Abandoned CA2243427A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8-308509 1996-11-19
JP30850996 1996-11-19

Publications (1)

Publication Number Publication Date
CA2243427A1 true CA2243427A1 (fr) 1998-05-28

Family

ID=17981889

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002243445A Abandoned CA2243445A1 (fr) 1996-11-19 1997-11-19 Derives de pyridinecarboxamide
CA002243427A Abandoned CA2243427A1 (fr) 1996-11-19 1997-11-19 Nouveaux derives de pyridinecarboxamide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002243445A Abandoned CA2243445A1 (fr) 1996-11-19 1997-11-19 Derives de pyridinecarboxamide

Country Status (8)

Country Link
US (2) US6046201A (fr)
EP (2) EP0882716B1 (fr)
JP (2) JP3258674B2 (fr)
KR (2) KR100481762B1 (fr)
CA (2) CA2243445A1 (fr)
DE (2) DE69712874T2 (fr)
TW (1) TW491841B (fr)
WO (2) WO1998022439A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310052B1 (en) 1996-06-04 2001-10-30 Queen's University At Kingston Nitrate esters and their use for neurological conditions
WO2003033471A1 (fr) * 2001-10-17 2003-04-24 Tobishi Pharmaceutical Co.,Ltd Nouveau derive de pyridone et agent therapeutique pour les maladies du systeme circulatoire les contenant
ATE528310T1 (de) * 2007-05-04 2011-10-15 Astrazeneca Ab Verfahren zur synthese von alkylphosphinsäuren durch initiierung eines amins und eines aminoxids
CN101280055B (zh) * 2008-04-30 2012-04-18 杭州油漆有限公司 高固低粘环保型醇酸树脂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994456A (en) * 1989-03-01 1991-02-19 Nisshin Flour Milling Co., Ltd. Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same
JP2843632B2 (ja) * 1989-03-01 1999-01-06 日清製粉株式会社 ピリジンカルボン酸アミド誘導体
JP2664238B2 (ja) * 1989-03-01 1997-10-15 日清製粉株式会社 ニコチン酸またはそのエステル誘導体
JPH03137095A (ja) * 1989-10-19 1991-06-11 Showa Denko Kk 気相エピタキシャル成長方法
JP2815126B2 (ja) * 1990-08-31 1998-10-27 日清製粉株式会社 ピリジンカルボン酸アミド誘導体
EP0473027B1 (fr) * 1990-08-31 1995-07-26 Nisshin Flour Milling Co., Ltd. Dérivés d'amides d'acides pyridinecarboxyliques et compositions pharmaceutiques les contenant
ATE220661T1 (de) * 1994-10-19 2002-08-15 Novartis Erfind Verwalt Gmbh Antivirale ether von aspartat-protease-substrat- isosteren

Also Published As

Publication number Publication date
EP0882716A1 (fr) 1998-12-09
US5972943A (en) 1999-10-26
TW491841B (en) 2002-06-21
KR19990077341A (ko) 1999-10-25
EP0885886B1 (fr) 2002-05-29
DE69712874T2 (de) 2002-10-10
DE69711853T2 (de) 2002-09-12
WO1998022440A1 (fr) 1998-05-28
DE69711853D1 (de) 2002-05-16
JP3258674B2 (ja) 2002-02-18
EP0882716A4 (fr) 2000-02-02
EP0885886A1 (fr) 1998-12-23
CA2243445A1 (fr) 1998-05-28
EP0882716B1 (fr) 2002-04-10
KR100481762B1 (ko) 2006-03-23
WO1998022439A1 (fr) 1998-05-28
EP0885886A4 (fr) 2000-02-02
US6046201A (en) 2000-04-04
KR19990077342A (ko) 1999-10-25
DE69712874D1 (de) 2002-07-04
JP3259916B2 (ja) 2002-02-25

Similar Documents

Publication Publication Date Title
JP6800872B2 (ja) リシルオキシダーゼ様２阻害剤とその使用
JP5124285B2 (ja) 細胞増殖性障害を処置する組成物および方法
DE69727308T2 (de) HETEROCYCLENDERIVATE DIE FAKTOR Xa HEMMEN
US5130317A (en) Pyrimidine-4,6-dicarboxylic acid diamides, processes for the use thereof, and pharmaceuticals based on these compounds
Duflos et al. N-Pyridinyl-indole-3-(alkyl) carboxamides and derivatives as potential systemic and topical inflammation inhibitors
WO2006041119A1 (fr) Dérivés d’hydrazide
IL180331A (en) 3-carbamoyl-2 pyridone derivatives, pharmaceutical compositions comprising them and uses thereof
CN105793253A (zh) 自分泌运动因子抑制剂化合物
KR20070116633A (ko) 피지디2 길항제 활성을 갖는 1-아세틱 애시드-인돌 유도체
JPS63246372A (ja) ３−ヘテロ置換−ｎ−ベンジル−インドール
EP1256576B1 (fr) Derives d'imidazolium fondus
KR20000065090A (ko) 3-알콕시피리딘-2-카복실산아미드에스테르,이의제조방법및약제로서의이의용도
JP3432753B2 (ja) 神経伝達物質放出増強薬としての新規な非環式アミド類
AU651629B2 (en) Tropolone derivatives and pharmaceutical composition thereof for preventing and treating ischemic diseases
EP0885886B1 (fr) Derives de pyridinecarboxamide
JPH09507846A (ja) フェニルメチルヘキサンアミドおよびその使用
JP2014518281A (ja) 電位依存性ナトリウムチャネル遮断薬
US5143926A (en) Substituted pyridine-2,4-dicarboxylic acid compounds and methods of use thereof
JP2656157B2 (ja) 認識増強に有用な新規な神経伝達物質放出剤
JP2002506879A (ja) 細胞接着性を調節する作用を有するケイ皮酸誘導体
AU631285B2 (en) Di(nitroxyalkyl)amides of pyridine-2,4- and -2,5-dicarboxylic acids, a process for the preparation thereof, and the use thereof
JP2002519420A (ja) 細胞接着性分子としてのケイ皮酸誘導体
KR102670554B1 (ko) 캐스파제 저해제로서의 신규한 이소인돌리논 유도체 화합물
JPS62135473A (ja) イミダゾ−ル縮合複素環化合物
ES2371358T3 (es) Compuesto de benzoimidazol capaz de inhibir prostaglandina d sintetasa.

Legal Events

Date Code Title Description
FZDE Discontinued